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Abstract
Background: Hepatitis C virus (HCV) currently infects approximately three percent of the world
population. In view of the lack of vaccines against HCV, there is an urgent need for an efficient
treatment of the disease by an effective antiviral drug. Rational drug design has not been the primary
way for discovering major therapeutics. Nevertheless, there are reports of success in the
development of inhibitor using a structure-based approach. One of the possible targets for drug
development against HCV is the NS3 protease variants. Based on the three-dimensional structure
of these variants we expect to identify new NS3 protease inhibitors. In order to speed up the
modeling process all NS3 protease variant models were generated in a Beowulf cluster. The
potential of the structural bioinformatics for development of new antiviral drugs is discussed.
Results: The atomic coordinates of crystallographic structure 1CU1 and 1DY9 were used as
starting model for modeling of the NS3 protease variant structures. The NS3 protease variant
structures are composed of six subdomains, which occur in sequence along the polypeptide chain.
The protease domain exhibits the dual beta-barrel fold that is common among members of the
chymotrypsin serine protease family. The helicase domain contains two structurally related beta-
alpha-beta subdomains and a third subdomain of seven helices and three short beta strands. The
latter domain is usually referred to as the helicase alpha-helical subdomain. The rmsd value of bond
lengths and bond angles, the average G-factor and Verify 3D values are presented for NS3 protease
variant structures.
Conclusions: This project increases the certainty that homology modeling is an useful tool in
structural biology and that it can be very valuable in annotating genome sequence information and
contributing to structural and functional genomics from virus. The structural models will be used
to guide future efforts in the structure-based drug design of a new generation of NS3 protease
variants inhibitors. All models in the database are publicly accessible via our interactive website,
providing us with large amount of structural models for use in protein-ligand docking analysis.
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Background
After the development of serological tests for hepatitis A
and B viruses in the 1970s it became clear that an addi-
tional agent accounted for approximately 90% of transfu-
sion-associated hepatitis (non-A non-B hepatitis,
NANBH) [1].
The novel agent, hence termed hepatitis C virus (HCV),
currently infects approximately 3% of the world's popula-
tion and it was classified within the Flavivirideae family.
Diagnostic tests for anti-HCV antibodies developed there-
after proved that HCV was indeed the predominant cause
of NANBH [2]. In view of the lack of vaccines against
HCV, there is an urgent need for a treatment of the disease
by an effective antiviral drug. This necessity has boosted
research on the structural biology of HCV with the pri-
mary focus being to identify possible targets for pharma-
ceutical intervention [3].
Rational drug design has not been the primary way for dis-
covering major therapeutics. However, recent successes in
the area give reason to expect that drug discovery projects
will increasingly be structure based. One of the possible
targets for drug development against HCV is the NS3 pro-
tease variants. HCV RNA is translated into a polyprotein
that during maturation is cleaved into functional compo-
nents. One component, nonstructural protein 3 (NS3), is
a 631-residue bifunctional enzyme with protease and hel-
icase activities.
The N-terminal portion of the NS3 protein was predicted
to contain a serine protease domain as judged from con-
served sequence patterns and by homology to Flavi- and
Pestiviruses [4-6]. The NS3 serine protease processes the
HCV polyprotein by both cis and trans mechanisms. The
interative refinement and optimization of drug leads is an
effective strategy for generating potent preclinical candi-
date [7,8]. Ongoing genome sequencing efforts have led
to the identification of hundreds of potential therapeutic
targets, many of which represent possible sources of cross-
over pharmacology. Homology or comparative modeling
is a key feature of an integrated drug discovery effort
because it allows this genomics information to be utilized
early in the development of target ligands or in the engi-
neering of ligand specificity [9].
Genome sequencing efforts are providing us with com-
plete genetic blueprints for hundreds of organisms,
including humans. We are now faced with assigning,
understanding and modifying the functions of proteins
encoded by these genomes. This task is generally facili-
tated by 3D structures [10], which are best determined by
experimental methods such as X-ray crystallography and
NMR spectroscopy. The theoretical approaches [11] can
be divided into physical and empirical methods. The
physical prediction methods are based on interactions
between atoms and include molecular dynamics and
energy minimization [12], whereas the empirical meth-
ods depend on the protein structures that have been
already determined by experiment. They include combi-
natorial [13] and comparative modeling [14,15].
Comparative modeling uses experimentally determined
protein structures to predict conformation of other pro-
teins with similar amino acid sequences. For modeling of
proteins was used restrained-based modeling imple-
mented in the program MODELLER [16]. The models
consist of coordinates for all non-hydrogen atoms in the
modeled part of a protein. Models are generated entirely
automatically in a four-step procedure [17]: (i) fold
assignment, (ii) sequence-structure alignment, (iii) model
building, and (iv) model evaluation. This procedure was
applied to variants of NS3 protease using Perl-CGI, C and
MPI programming.
We modeled the structure of variants of NS3 protease var-
iants available in the National Center for Biotchnology
Information (Genbank), using structural bioinformatics
tools. Knowledge of the three-dimensional structure vari-
ants will undoubtedly aid the design of useful inhibitors
that may be used as a drug against hepatitis C virus. In
order to speed up the modeling process all NS3 models
were generated in a Beowulf cluster (BioComp, S.J. Rio
Preto, Brazil). The potential of the structural bioinformat-
ics for development of new antiviral drugs is discussed.
Results and discussion
Primary sequence comparasion
The identity between the sequences of a bifunctional pro-
tease structure (PDB access codes:1CU1, 1DY9) [31,38]
(templates) and NS3 protease variants (targets) is shown
in Table 1. The secondary structural elements are indi-
cated in the Figure 2 without inhibitor and in the Figure 3
with inhibitor. The sequence from crystallographic struc-
ture 1CU1 shows more than 79.1% identity with the
sequences of NS3 protease variants, which provide high
accuracy for the models (Table 1).
Quality of the models
The atomic coordinates of crystallographic structure
1CU1 solved to resolution of the 2.5 Å were used as start-
ing model for modeling of the NS3 protease variant struc-
tures, and the structure of NS3 complexed with an
inhibitor (PDB access code: 1DY9) was used to generate
homology models for docking studies. Binding of an
inhibitor to the active site of an enzyme is typically con-
nected with local and possibly also global structural rear-
rangement of the enzyme (induced-fit mechanism).
Therefore structure-based drug design preferentially relies
on the crystal structures of enzyme-inhibitor complexesBMC Structural Biology 2005, 5:1 http://www.biomedcentral.com/1472-6807/5/1
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containing bound inhibitors of similar chemical struc-
tures to the compounds being designed. Such complexes
offer more detailed and accurate picture of the inhibitor-
enzyme interactions and structural complementarity
between the inhibitor and the active site. The homology
models of the variants of NS3 protease which used the
NS3 complexed with an inhibitor are more adequate to
docking simulations. The atomic coordinates of all water
molecules were removed from the templates.
The analysis of the Ramachandran diagram φ-ψ plots of
the 1CU1 structure (template) were used to compare the
overall stereochemical quality of the NS3 protease vari-
ants structures against template solved by biocrystallogra-
phy (Table 1). They present over 94.0% of the residues in
the most favorable regions. The same analysis for crystal-
lographic structure (1CU1) present 88.9% of residues in
the most favorable, 10.5% additional allowed regions,
0.6% generously allowed regions, and 0.0% disallowed
regions, which strongly indicates that the molecular mod-
els present good overall stereochemical quality.
Overall description
The NS3 protease variant structures are composed of six
subdomains, which occur in sequence along the polypep-
tide chain (Figure 2 and 3). The protease domain exhibits
the dual β-barrel fold that is common among members of
the chymotrypsin serine protease family. The helicase
domain contains two structurally related β-α-β sub-
domains and a third subdomain of seven helices and
three short β strands. The latter domain is usually referred
to as the helicase α-helical subdomain. The 13-residue
protease activation domain of NS4A contributes one
strand to the N-terminal protease β-barrel and is consid-
ered to be the sixth subdomain [31].
Differences in subdomain structure in the NS3 protease
variant molecule and in the structures of the isolated pro-
tease and helicase domains were assessed in several ways.
The strucuture of NS3 protease without inhibitor Figure 2
The strucuture of NS3 protease without inhibitor. 
The structure of NS3 protease variant, an engineered mole-
cule that consists of 631 NS3 residues. It has six subdomains: 
two β barrels in the protease domain (down); two β-α-β 
subdomains (up on the left) and one α-helical subdomain in 
the helicase (up on the right). The figure was generated by 
Molmol [37].
The strucuture of NS3 protease complexed with 5,5-di- fluoro-2-keto-3-aminopentanoic acid Figure 3
The strucuture of NS3 protease complexed with 5,5-
di-fluoro-2-keto-3-aminopentanoic acid. The NS3 pro-
tease-inhibitor complex shows the interaction between ser-
ine protease domain with 5,5-di-fluoro-2-keto-3-
aminopentanoic acid. All models were generated using Par-
model [39].BMC Structural Biology 2005, 5:1 http://www.biomedcentral.com/1472-6807/5/1
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Inspection of the molecule revealed that the subdomain
folds are similar. Overall preservation of structure is also
apparent when the subdomains from the various struc-
tures are superposed [31].
The rmsd value of bond lengths and bond angles, the
average G-factor and Verify 3D values are shown in Table
2 for NS3 protease variants structures. The same analysis
for crystallographic structure (1CU1) present rmsd values
Table 1: Analysis of the Ramachandran plot and identity between template and models of NS3 protease variants. The accuracy of 
comparative modeling is related to the percentage of sequence identity on which the model is based, correlating with the relationship 
between the structural and sequence similarities of two proteins. High accuracy comparative models are based on >50% sequence 
identity to their templates. They tend to have ~1 Å r.m.s. error for the main-chain atoms, which is comparable to the accuracy of a 
medium-resolution NMR structure or a low-relosution X-ray structure. All structure models in the database were generated using 
alignments with more than 79% sequence identity, which generating models with high accuracy.
Genbank access 
code
Residue Range Identity (%) Region of the Ramachandran plot (%)
Most Favorable Additional 
Allowed
Generously 
Allowed
Disallowed
AJ238800 1027 – 1657 95.0 94.9 5.1 0.0 0.0
AJ238799 1027 – 1657 95.7 95.1 4.6 0.2 0.2
AF139594 1028 – 1658 95.7 95.8 3.8 0.2 0.2
D17763 1033 – 1663 80.5 94.9 4.9 0.2 0.0
AF054247 1027 – 1657 94.0 95.0 4.8 0.2 0.0
AF054248 1027 – 1657 93.8 94.9 5.1 0.0 0.0
AF054249 1027 – 1657 93.8 95.2 4.8 0.0 0.0
D50409 1031 – 1661 80.3 95.1 4.9 0.0 0.0
D84262 1032 – 1662 84.2 95.0 5.0 0.0 0.0
D84263 1025 – 1665 83.1 95.2 4.8 0.0 0.0
D84264 1029 – 1659 83.9 95.2 4.8 0.0 0.0
D84265 1027 – 1657 82.5 94.9 5.1 0.0 0.0
D10749 1027 – 1657 90.5 94.9 5.1 0.0 0.0
D13558 1027 – 1657 94.1 94.8 5.2 0.0 0.0
D14853 1027 – 1657 88.8 95.3 4.7 0.0 0.0
D00944 1031 – 1661 79.8 95.1 4.9 0.0 0.0
D10988 1031 – 1661 79.7 95.1 4.9 0.0 0.0
AF046866 1033 – 1663 80.3 94.7 5.1 0.2 0.0
D49374 1035 – 1665 79.8 94.7 5.1 0.2 0.0
Y11604 1027 – 1657 84.7 95.4 4.6 0.0 0.0
Y13184 1028 – 1658 82.3 95.2 4.8 0.0 0.0
Y12083 1031 – 1661 81.9 94.6 5.2 0.0 0.2
U16362 1027 – 1657 92.6 95.2 4.6 0.2 0.0
U45476 1027 – 1657 94.7 94.9 5.1 0.0 0.0
AJ000009 1027 – 1657 95.2 95.1 4.9 0.0 0.0
M67463 1027 – 1657 89.6 94.9 4.9 0.2 0.0
D63822 1031 – 1661 79.2 95.2 4.8 0.0 0.0
D63821 1032 – 1662 79.1 94.7 5.1 0.2 0.0
D14484 1027 – 1657 94.3 95.8 4.2 0.0 0.0
D11168 1027 – 1657 94.9 95.0 5.0 0.0 0.0
D11355 1027 – 1657 94.6 95.0 5.0 0.0 0.0
D50480 1027 – 1657 93.5 95.0 5.0 0.0 0.0
D50481 1027 – 1657 94.6 95.4 4.6 0.0 0.0
D50482 1027 – 1657 94.7 95.5 4.3 0.2 0.0
D50483 1027 – 1657 93.6 95.2 4.8 0.0 0.0
D50485 1027 – 1657 94.3 95.6 4.4 0.0 0.0
D50484 1027 – 1657 94.1 95.3 4.7 0.0 0.0
D28917 1033 – 1663 80.5 95.2 4.6 0.2 0.0
D30613 1027 – 1657 93.8 95.4 4.6 0.0 0.0
D10934 1027 – 1657 95.2 95.3 4.7 0.0 0.0
AF207762 1027 – 1657 94.0 95.1 4.9 0.0 0.0BMC Structural Biology 2005, 5:1 http://www.biomedcentral.com/1472-6807/5/1
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of the 0.013Å bond lengths and 1.67°, the average G-fator
values of the 0.14 torsion angles and 0.28 covalent geom-
etry, and Verify 3D values of the 321.53 score total and
1.09S quality.
Database design, access, and interface
A MySQL database based on relational database manage-
ment system (RDBMS) was developed to archive protein
structure identified in infectious agents such as NS3
protease variants from hepatitis C virus. All supporting
Table 2: Analysis of the rmsd from ideal geometry, 3D Profile, and G-factor.
Genbank access 
code
Residue Range rmsd 3D Profile* G-factor**
Bond Lengths 
(Å)
Bond Angles (°) Total Score Sideal Score Torsion Angles Covalent 
Geometry
AJ238800 1027 – 1657 0.020 2.171 299.14 1.03S 0.01 -0.17
AJ238799 1027 – 1657 0.021 2.425 166.68 0.58S 0.07 -0.21
AF139594 1028 – 1658 0.021 2.193 152.89 0.53S 0.09 -0.20
D17763 1033 – 1663 0.019 2.143 290.96 1.00S 0.03 -0.14
AF054247 1027 – 1657 0.020 2.162 288.28 1.00S 0.07 -0.16
AF054248 1027 – 1657 0.020 2.194 292.48 1.01S 0.01 -0.19
AF054249 1027 – 1657 0.020 2.207 290.64 1.00S 0.05 -0.18
D50409 1031 – 1661 0.020 2.188 287.09 0.99S 0.02 -0.17
D84262 1032 – 1662 0.020 2.181 276.59 0.95S 0.06 -0.17
D84263 1025 – 1665 0.020 2.173 283.17 0.98S 0.01 -0.16
D84264 1029 – 1659 0.020 2.174 296.59 1.02S 0.03 -0.15
D84265 1027 – 1657 0.020 2.155 277.67 0.96S 0.02 -0.15
D10749 1027 – 1657 0.020 2.589 287.57 0.99S 0.02 -0.16
D13558 1027 – 1657 0.020 2.157 280.60 0.97S 0.04 -0.15
D14853 1027 – 1657 0.020 2.168 274.13 0.95S 0.02 -0.16
D00944 1031 – 1661 0.020 2.149 287.90 0.99S 0.40 -0.15
D10988 1031 – 1661 0.020 2.171 287.55 0.99S 0.02 -0.16
AF046866 1033 – 1663 0.020 2.957 281.07 0.97S 0.03 -0.16
D49374 1035 – 1665 0.020 2.163 292.23 1.01S 0.02 -0.15
Y11604 1027 – 1657 0.020 2.382 281.93 0.97S 0.02 -0.16
Y13184 1028 – 1658 0.020 2.166 296.66 1.02S 0.02 -0.15
Y12083 1031 – 1661 0.020 2.271 290.58 1.00S -0.01 -0.21
U16362 1027 – 1657 0.020 2.186 280.49 0.97S 0.01 -0.16
U45476 1027 – 1657 0.020 2.398 281.26 0.97S 0.03 -0.17
AJ000009 1027 – 1657 0.020 2.168 290.86 1.00S 0.03 -0.16
M67463 1027 – 1657 0.020 2.139 281.59 0.97S 0.03 -0.14
D63822 1031 – 1661 0.020 2.385 284.43 0.98S 0.03 -0.16
D63821 1032 – 1662 0.020 2.420 269.09 0.93S 0.03 -0.18
D14484 1027 – 1657 0.020 2.234 285.83 0.99S 0.00 -0.19
D11168 1027 – 1657 0.020 2.160 289.57 1.00S 0.04 -0.15
D11355 1027 – 1657 0.020 2.148 306.49 1.06 0.04 -0.14
D50480 1027 – 1657 0.020 2.123 291.79 1.01S 0.05 -0.13
D50481 1027 – 1657 0.020 2.151 277.60 0.96S 0.06 -0.14
D50482 1027 – 1657 0.020 2.172 284.69 0.98S 0.03 -0.16
D50483 1027 – 1657 0.020 2.149 291.04 1.00S 0.06 -0.15
D50485 1027 – 1657 0.020 2.138 293.16 1.01S 0.03 -0.14
D50484 1027 – 1657 0.020 2.204 289.47 1.00S 0.00 -0.17
D28917 1033 – 1663 0.020 2.221 295.32 1.02S 0.03 -0.19
D30613 1027 – 1657 0.020 2.248 282.94 0.98S 0.02 -0.20
D10934 1027 – 1657 0.020 2.434 289.87 1.00S 0.00 -0.18
AF207762 1027 – 1657 0.020 2.367 308.61 1.07S 0.04 -0.15
*Total Score: is the sum of the 3D-1D scores (statistical preferences) of each residue present in protein. Ideal Score: Sideal = exp(-
0.83+1.008xln(L)); where L is number of amino acids.
Sideal Score: is compatibility of the sequence with their 3D structure. It is obtained Total Score / Ideal Score. Sideal Score above 0.45Sideal.
**Ideally, scores should be above -0.5. Values below -1.0 may need investigation.BMC Structural Biology 2005, 5:1 http://www.biomedcentral.com/1472-6807/5/1
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data related to the 3D structures modeling, such as protein
codes, atomic coordinates in PDB format from modeled
proteins, fasta sequence, links to others databases and var-
ious information about the protein were arranged in the
MySQL [32] database under a master table. The aim this
database is to provide access to a collection of annotated
models generated by automated homology modelling of
NS3 protease variants from hepatitis C virus. All models
in the database are publicly accessible via our interactive
website (Figure 1) [33]. The database user interface pro-
vides user friendly menus, so that all information can be
printed in one step from any standard web browser. A
small ribbon representation is included to obtain a first
impression of the model structure (Figure 2 and 3).
Atomic coordinates for the homology models can be
downloaded in PDB format and their primary sequence in
fasta format. The fields are defined with links to the target
sequence, the template structure entries in PDB [34],
structural information and analysis. There are two hom-
ology models for each sequence in the database, one
obtained using 1CU1 as template and other using 1DY9
as template. The second model is adequade for docking
simulation, since it was used as template a structure com-
plexed with an inhibitor (PDB access code: 1DY9).
Conclusions
Large scale protein homology modeling, in which whole
sequence databases or whole genomes are used as input
into automated modeling algorithms, have been reported
by several groups [35]. By utilizing powerful computer
systems with multiple processors, these efforts have
allowed the creation of large databases of homology mod-
els of proteins. This project increases the certainty that
homology modeling is an useful tool in structural biology
and that it can be very valuable in annotating genome
sequence information and contributing to structural and
functional genomics from virus, bacteria and other
organisms.
Database interface Figure 1
Database interface. The database user interface provides user friendly menus. In the menu of main page there are links to 
NS3 protein variant access codes of the Genbank, which lead to another page with the structural information and analysis 
about the generated model, such as a small ribbon representation, the atomic coordinates (model and template), and sequence 
in fasta format (model). The accuracy of the model can be viewed at link "NS3 protease variant table results" which shows 
results of values of the 3D Profile, rmsd, G-factor, and Ramachandran plot for each model.BMC Structural Biology 2005, 5:1 http://www.biomedcentral.com/1472-6807/5/1
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Inhibition studies have shown that NS3 is only modestly
inactivated by classic serine protease inhibitors such as
chloromethylketones or phenylmethyl sylfonylfluoride
[36]. The structural models will be used to guide future
efforts in the structure based design of a new generation of
NS3 protease variants inhibitors. This database is freelly
available for all users on the Web, providing us with large
amount of structural models for use in protein-ligand
docking analysis.
Methods
Molecular modeling
Molecular modeling is usually the method of choice when
there is a clear relationship of homology between the
sequence of a target protein and at least one known struc-
ture. This computational technique is based on the
assumption that tertiary structures of two proteins will be
similar if their sequences are related, and it is the
approach most likely to give accurate results [18]. There
are two main approaches to homology modeling: (1) frag-
ment-based comparative modeling [14,19] and (2)
restrained-based modeling [16]. For modeling of NS3
protease variants from hepatitis C virus we used the sec-
ond approach. Model building of NS3 protease variants
was carried out using the program MODELLER [16].
MODELLER is an implementation of an automated
approach to comparative modeling by satisfaction of spa-
tial restraints [20-22]. The modeling procedure begins
with an alingment of the sequence to be modeled (target)
with related known three-dimensional structure (tem-
plates). This alignment is usually the input to the pro-
gram. The output is a three-dimensional model for the
target sequence containing all main-chain and sidechain
non-hydrogen atoms.
Next, the spatial restraints and CHARMM energy terms
enforcing proper stereochemistry [23] were combined
into an objective function. Finally, the model is obtained
by optimizing the objective function in Cartesian space.
The optimization is carried out by the use of the variable
target function method [24] employing methods of con-
jugate gradients and molecular dynamics with simulated
anneling. Several slightly different models can be calcu-
lated by varying the initial structure. A total of 1000 mod-
els were generated for each enzyme and the final models
were selected based on stereochemical quality. All optimi-
zation process was performed on a Beowulf cluster with
16 nodes (BioComp, AMD Athlon XP 2100+).
Analysis of the models
The overall stereochemical quality of the final models for
each NS3 protease variants from hepatitis C virus was
acessed by the program PROCHECK [25]. The root mean
square deviations (rmsd) differences from ideal
geometries for bond lengths and bond angles were calcu-
lated with X-PLOR [26,27]. G-factor value is essentially
just log-odds score based on the observed distributions of
the stereochemical parameters. It was computed for the
following properties: torsion angles (the analyses pro-
vided the observed distributions of φ-δ, χ1-χ2, χ-1, χ-3, χ-4
and ω values for each of the 20 amino acid types) and cov-
alent geometry (for the main-chain, bond lengths and
bond angles) these average values were calculated using
PROCHECK [25]. The Verify-3D measures the compati-
bility of a protein model with its sequence, these values
were calculated using 3D profile [28-30].
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